Middleton and Carlson discussed various product developments that were presented during the meeting, including NK-based cell therapies, various CAR T-cell therapies, directed evolution of capsid discovery, and plasmid DNA products, to name a few.

The two also discussed how several companies are working on the transition from small-scale boutique therapies to treatments for diseases that impact millions of people. This inclusive effort requires innovations in components such as viral vectors, stem cell, and allogeneic immunotherapies. Many organizations are attempting to scale up and automate as much of the manufacturing process as possible. Ultimately, as Middleton and Carlson discuss, the goal is to transition from a very hands-on, labor-intensive process to a more factory automated, large-scale process.

To stay up to date on the latest business happenings in the cell and gene therapy industry, check out Cell & Gene Therapy Business Outlook today!

Opportunities abound in cell and gene therapy for discerning investors
CARLSBAD, CA - There are more opportunities in the cell and gene therapy sector than ever before. But to profit from them, investors must be more discerning...

Catching up with the Alliance for Regenerative Medicine at Cell & Gene Meeting on the Mesa
CARLSBAD, CA - What's going on at this week's Cell & Gene Meeting on the Mesa? ScienceBoard.net spoke with Stephen Majors, director of public...

What's next for cellular immunotherapies?
CARLSBAD, CA - What's the next step in the development of cellular immunotherapies, particularly for liquid and solid tumors? At this week's Cell & Gene...

Dialogue with regulators will help bring cell and gene therapies to market
CARLSBAD, CA - Open engagement and frequent communication with regulators is needed throughout the development process for cell and gene therapies to...